Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year?
10:40am, Monday, 02'nd Feb 2026
Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.
SG Americas Securities LLC Sells 30,225 Shares of Alkermes plc $ALKS
06:23am, Tuesday, 20'th Jan 2026
SG Americas Securities LLC cut its holdings in Alkermes plc (NASDAQ: ALKS) by 49.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Co
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
10:40am, Thursday, 15'th Jan 2026
Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Wednesday, 14'th Jan 2026
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Best Value Stocks to Buy for Jan.14
04:35am, Wednesday, 14'th Jan 2026
GES, NESR and ALKS made it to the Zacks Rank #1 (Strong Buy) value stocks list on Jan.14, 2026.
Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:25pm, Tuesday, 13'th Jan 2026
Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes
04:05pm, Monday, 12'th Jan 2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Alkermes (NASDAQ:ALKS) EVP Sells $150,000.00 in Stock
05:52am, Sunday, 11'th Jan 2026
Alkermes plc (NASDAQ: ALKS - Get Free Report) EVP Craig Hopkinson sold 5,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $30.
Alkermes plc $ALKS Shares Bought by Robeco Institutional Asset Management B.V.
05:00am, Sunday, 11'th Jan 2026
Robeco Institutional Asset Management B.V. lifted its holdings in shares of Alkermes plc (NASDAQ: ALKS) by 18.6% during the undefined quarter, according to its most recent disclosure with the Securiti
Alkermes: Avadel Deal And Vibrance-2 Unlock Upside
09:16pm, Thursday, 08'th Jan 2026
Alkermes is transforming into a fully integrated biopharma, leveraging Vibrance-2 results and the Avadel acquisition for competitive advantage in sleep medicine. ALKS's robust legacy portfolio funds r
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug
12:46pm, Wednesday, 07'th Jan 2026
Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
07:00am, Tuesday, 06'th Jan 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of n
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:00pm, Tuesday, 30'th Dec 2025
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthc
NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Are Investors Undervaluing Alkermes (ALKS) Right Now?
10:41am, Monday, 08'th Dec 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
